The impact of chronic kidney disease on lipid management and goal attainment in patients with atherosclerosis diseases in Taiwan

International Journal of Medical Sciences

Volumn 11, Issue 4, 2014, Pages 381-388

  Lin, Tsung Hsien ^a,b   Chuang, Shao Yuan ^c   Chu, Chun Yuan ^a   Lee, Wen Hsien ^a   Hsu, Po Chao ^a,b   Su, Ho Ming ^a,b   Li, Yi Heng ^d   Fang, Ching Chang ^e   Wang, Kuo Yang ^f   Tseng, Wei Kung ^g   Li, Ai Hsien ^h   Ueng, Kwo Chang ⁱ   Hsieh, I Chang ^j   Huang, Lien Chi ^k   Wang, Chiun Hsiung ^k   Pan, Wen Harn ^c   Yeh, Hung I ^l   Wu, Chau Chung ^m   Yin, Wei Hsian ⁿ   Chen, Jaw Wen ⁿ  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c ACADEMIA SINICA   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^e TAINAN MUNICIPAL HOSPITAL   (Taiwan)

^f TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^g E DA HOSPITAL   (Taiwan)

^h FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

ⁱ CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^j CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^k TAIPEI CITY HOSPITAL   (Taiwan)

^l MACKAY MEMORIAL HOSPITAL   (Taiwan)

^m NATIONAL TAIWAN UNIVERSITY   (Taiwan)

ⁿ NATIONAL YANG MING UNIVERSITY   (Taiwan)

more..

Author keywords

Atherosclerosis; Chronic kidney disease; Goal; Lipid

Indexed keywords

ACETYLSALICYLIC ACID; ACIPIMOX; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CLOPIDOGREL; COLESTYRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AGED; ARTICLE; ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONTROLLED STUDY; DISEASE CONTROL; DRUG USE; DYSLIPIDEMIA; FEMALE; GLUCOSE INTOLERANCE; GOAL ATTAINMENT; HEART FAILURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; SEX; TAIWAN; TRIACYLGLYCEROL BLOOD LEVEL;

ATHEROSCLEROSIS.; CHRONIC KIDNEY DISEASE; GOAL; LIPID;

ATHEROSCLEROSIS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MULTIVARIATE ANALYSIS; RENAL INSUFFICIENCY, CHRONIC; TAIWAN; TRIGLYCERIDES;

EID: 84896737477     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.7069     Document Type: Article

References (25)

1. El Nahas AM, Bello AK. Chronic kidney disease: The global challenge. Lancet 2005;365:331-40.
2. Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: Approaches and initiatives-A position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007;72:247-59.
3. USRDS. International comparisons. In: United Stated Renal Data System Annual Data Report. Bethesda, MD: The National Institute of Health, National Institute of Diabetes and Digestive and Kidney Disease. 2009;344-55.
4. Hwang SJ, Tsai JC, Chen HC. Epidemiology, impact and preventive care of chronic kidney disease in Taiwan. Nephrology (Carlton). Suppl 2010;2:3-9.
5. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, et al. ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769-818.
6. Tonelli M, Muntner P, Lloyd A, et al. Alberta Kidney Disease Network. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380:807-14.
7. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001;59:260-9
8. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J. 2010;160:785-794.
9. Yin WH, Wu CC, Chen JW. Registry of lipid control and the use of lipid-lowering drugs for secondary prevention of cardiovascular events in patients with established atherosclerotic disease in Taiwan: Rationality and methods. Int J Gerontol 2012;6:241-246.
10. Levey AS, Greene T, Kusek JW. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000;11:A0828.
11. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-266.
12. Kidney Disease Outcomes Quality Initiative Group. K/DOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease. Am J Kidney Dis. 2003;41:S1eS91.
13. Grundy SM, Cleeman JI, Merz CN, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-39.
14. Navaneethan SD, Pansini F, Perkovic V, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2009;2:CD007784.
15. Palmer SC, Craig JC, Navaneethan SD, et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157:263-75.
16. KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49(2 Suppl 2):S12-154.
17. Park SH, Kim W, Park CS, et al. A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol. 2009;104: 1292-1295.
18. Angiolillo DJ, Bernardo E, Capodanno D, et al. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol. 2010;55: 1139-1146.
19. Kaufman JS, Fiore L, Hasbargen JA, O'Connor TZ, Perdriset G. A pharmacodynamic study of clopidogrel in chronic hemodialysis patients. J Thromb Thrombolysis. 2000;10:127-131.
20. Cuisset T, Frere C, Moro PJ, et al. Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after Acute Coronary Syndrome. Thromb Res. 2010;126:e400-2.
21. Keltai M, Tonelli M, Mann JF, et al. CURE Trial Investigators. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. Eur J Cardiovasc Prev Rehabil. 2007;14:312-8.
22. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety ofmore intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet 2010;376:1670-1681.
23. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular diseasebut with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009;338:b2376.
24. Waters DD, Brotons C, Chiang CW, et al. Lipid Treatment Assessment Project 2 Investigators. Lipid treatment assessmentproject 2: a multinational survey to evaluate the proportion of patientsachieving low-density lipoprotein cholesterol goals. Circulation. 2009;120:28-34.
25. Yan AT, Yan RT, Tan M, et al. Vascular Protection (VP) and Guidelines Oriented Approach to Lipid Lowering (GOALL) Registries Investigators. Contemporary management of dyslipidemiain high-risk patients: targets still not met. Am J Med. 2006;119:676-683.